Personalizing the Use of a Intermittently Scanned Continuous Glucose Monitoring Device in Individuals With Type 1 Diabetes: A Cost-Effectiveness Perspective in the Netherlands (FLARE-NL 9)
Authors' conclusion
Comparing subgroups of isCGM users allows to prioritize them based on cost-effectiveness. The most cost-effective subgroup was occupation-related indications, followed by multiple indications, high HbA1c and the frequent hypoglycemic events subgroups. However, controlled studies with larger sample size are needed to draw definitive conclusions.
Study context
- Population
- Persons with T1D initiating intermittently scanned continuous glucose monitoring (isCGM), nationwide Dutch prospective observational study linked to insurance records
- Participants
- 381 persons
- Exposure
- 12 months after vs 12 months before isCGM initiation, by indication subgroup
- Outcome
- Incremental cost-effectiveness ratios (ICERs) (costs per QALY gained, HRQoL by EQ-5D-3L) for total cohort and each subgroup
- Follow-up
- 12 months before and after isCGM initiation
Methodological detailsreal-world, nationwide, before-after comparison (12 months before and after isCGM initiation), societal and healthcare payer perspectives, willingness to pay €50,000 per quality-adjusted life year (QALY)
- Real-world
- Nationwide
- Before-after comparison (12 months before and after isCGM initiation)
- Societal and healthcare payer perspectives
- Willingness to pay €50,000 per QALY
Main finding
As reported in the abstract
Cost-effectiveness of isCGM, societal perspective
- isCGM dominant (higher health-related quality of life (HRQoL) gain with lower costs) in all subgroups except subgroup 1 (frequent hypoglycemic events)
Observational data: associations, not effects.
Further findings
Probability of isCGM being cost-effective, healthcare payer perspective
- Probability of isCGM being cost-effective, healthcare payer perspective: Total cohort 16%
Sensitivity analyses
- Most sensitivity analyses confirmed these findings
Original publication
Personalizing the Use of a Intermittently Scanned Continuous Glucose Monitoring Device in Individuals With Type 1 Diabetes: A Cost-Effectiveness Perspective in the Netherlands (FLARE-NL 9). J Diabetes Sci Technol. Published 9 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →